Abcam plc
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Alan Thomas Hirzel BS,
- Full Time Employees
- 1,760
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- Discovery Drive Cambridge United Kingdom CB2 0AX
- IPO Date
- Oct 22, 2020
- CIK
- 0001492074
- Website
- abcam.com
- Similar Companies
- Business
- Abcam plc (Nasdaq: ABCM), a Danaher Corporation company, produces and distributes high-quality antibodies, proteins, reagents and associated research tools for life science researchers worldwide. The company offers primary and secondary antibodies, recombinant monoclonal antibodies, ELISA kits and immunoassays including SimpleStep ELISA, matched antibody pairs, knockout cell lines, proteins and peptides, lysates, biochemicals, cellular assays, epigenetics kits such as FirePlex Multiplex miRNA Kits, accessories and reagents; its portfolio supports research in cancer, cardiovascular disease, chromatin and nuclear signaling, immunology, neuroscience, stem cells, neurological disorders, infectious diseases and metabolic disorders. Founded in 1998 and headquartered in Cambridge, UK, Abcam operates from 13 global locations including manufacturing facilities, serving over 750,000 researchers in more than 130 countries with over 110,000 products that combine biology, validation data, peer-reviewed citations and expert support. In 2023, Danaher Corporation acquired Abcam for $5.7 billion, a transaction that completed in late 2023, positioning Abcam as a standalone entity within Danaher's Life Sciences segment to enhance innovation in protein consumables, antibody portfolios and drug discovery tools while leveraging the Danaher Business System.
Molecular Instruments and Abcam Announce Broad Compatibility of the HCR™ HiFi Encoder with Abcam's Best-in-Class RabMAb® and Mouse Antibody Portfolio
Metabolism Assays Market Size Projected to Reach USD 3.1 Billion by 2034, Growing Steadily at 6.7% CAGR | Report by Transparency Market Research, Inc
Danaher completes $5.7 billion acquisition of Abcam
Danaher Completes Acquisition of Abcam
Acquisition of Abcam by Danaher Approved by the High Court of Justice of England and Wales
Statement from Dr. Jonathan Milner on the suspension of the “Vote AGAINST” campaign
Jonathan Milner Issues Statement Responding to the Glass Lewis Report
Jonathan Milner Issues Statement Responding to ISS Report
Jonathan Milner releases presentation to Abcam plc shareholders, outlining reasons to reject Danaher's bid and strategic vision for the Company
Exlusive: Why Abcam founder believes Danaher's acquisition offer falls short
ABCAM INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Abcam plc - ABCM
Jonathan Milner issues Open Letter to shareholders of Abcam plc
GMED or ABCM: Which Is the Better Value Stock Right Now?
Jonathan Milner issues Open Letter to shareholders of Abcam plc
Abcam plc Statement on Dr. Jonathan Milner's Announcement
Dr. Jonathan Milner opposes Danaher's acquisition of Abcam and calls for EGM to replace Board
Abcam plc Interim Results for the Six-Month Period Ended 30 June 2023
ABCAM INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Abcam plc - ABCM
Danaher Buys Abcam for $5.7 Billion to Expand Its Product Offerings
ABCM Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Abcam plc Is Fair to Shareholders